The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire.
about
Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccinesAn MVA vaccine overcomes tolerance to human p53 in mice and humans.IL-2 mediates CD4+ T cell help in the breakdown of memory-like CD8+ T cell tolerance under lymphopenic conditionsNonspecific down-regulation of CD8+ T-cell responses in mice expressing human papillomavirus type 16 E7 oncoprotein from the keratin-14 promoter.Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells.Tumour immunotherapy: new tools, new treatment modalities and new T-cell antigens.The role of p53 in the immunobiology of cutaneous squamous cell carcinoma.Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response.Immunotherapy exploiting the versatility of dendritic cells.Interaction of streptavidin-based peptide-MHC oligomers (tetramers) with cell-surface TCRsRecombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion.Insights into T cell recognition of antigen: significance of two-dimensional kinetic parametersGene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes.Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune responseTelomerase immunity from bench to bedside: round one.A comparison and critical analysis of preclinical anticancer vaccination strategies.Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapyDevelopment of multi-epitope vaccines targeting wild-type sequence p53 peptides.Induction of tolerance to immunogenic tumor antigens associated with lymphomagenesis in HOX11 transgenic mice.Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses.Colorectal cancer vaccines in clinical trials.Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients.Specific killing of P53 mutated tumor cell lines by a cross-reactive human HLA-A2-restricted P53-specific CTL line.Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53.Soluble MHC-peptide complexes: tools for the monitoring of T cell responses in clinical trials and basic research.Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial.Exploring the MHC-peptide matrix of central tolerance in the human thymus.Recombinant human single-chain MHC-peptide complexes made from E. coli By in vitro refolding: functional single-chain MHC-peptide complexes and tetramers with tumor associated antigens.Phenotype of p53 wild-type epitope-specific T cells in the circulation of patients with head and neck cancerDifferent T Cell Receptor Affinity Thresholds and CD8 Coreceptor Dependence Govern Cytotoxic T Lymphocyte Activation and Tetramer Binding Properties
P2860
Q26738680-AA726E56-ED87-4977-8C8A-2AAE5255C7A0Q33269028-75991448-6036-44FF-A7AA-67D8194E28C8Q33697777-C7E14F3D-438F-4695-BB26-1E66DC3788EDQ33842444-19805642-61DC-444B-8BE6-4C4D1B6A93F6Q34155839-142DAB52-C204-4B37-B02A-072DF9EA46B2Q34265381-162AD1FE-8660-4D5D-BE52-56C1D102CE03Q35142669-4874B39D-4101-4EE5-B67C-45DD34C0BD8EQ35182373-14320CA5-4E64-4248-900F-7D92A7CDABA8Q35201914-05ED726F-A0DF-4614-8AE2-05B45DB0D066Q35612835-C3F39E61-A619-4FB9-BB88-C08AB49E234DQ35677112-94F8CF1F-4A62-45A3-9EE4-CE7AF1C970A9Q35927615-09056F57-4953-471C-B38D-13CEAE5383BCQ36327157-7582E6BD-1410-4105-94DB-D488FD07346CQ36402967-CAAE9692-7854-4FA6-B35F-9D92D2769C0EQ36745749-8AC60449-51D1-44E5-963E-CE45274DA986Q36951547-7BB3D671-037D-47FD-B7F4-F09448B37C70Q36954938-F5C39760-AA56-4DE2-8513-4D2A059C54ACQ37259621-D5F8482F-AD8E-4B5A-B3ED-40F6A0FD7AD6Q37291942-17D69165-45C5-4532-BC24-E0FC17F41037Q37729146-2AA48703-9CE5-4252-A7F3-C280981907F9Q37892600-DFA6289C-9BB2-41C6-93A5-ACAF2EDA76E3Q40143296-4B0E1CEB-938D-4E4F-974B-F77B1B789535Q40784250-FEDB003E-2AD6-4B34-B5AE-AA9F84F43E0EQ40812116-8429D963-944E-45C1-9975-907E5BE9AF52Q42017582-F9DB220A-F441-4360-AD3F-E00184DE3A04Q44426842-585D37BD-E3A6-457D-B2BD-EC314DFFB7ACQ45929502-A3241606-CC17-4778-9DEB-36ADD4CCF168Q55239887-4199AC85-5D45-468E-8FA8-E77A4BEC68D7Q56956550-3DFC7DDF-CE34-4B82-A5BB-D4A5A29629E2Q57372665-9D330A6F-4C70-45FD-A8C7-635C3102B897
P2860
The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
The use of HLA A2.1/p53 peptid ...... lerance on the TCR repertoire.
@en
type
label
The use of HLA A2.1/p53 peptid ...... lerance on the TCR repertoire.
@en
prefLabel
The use of HLA A2.1/p53 peptid ...... lerance on the TCR repertoire.
@en
P2093
P1476
The use of HLA A2.1/p53 peptid ...... lerance on the TCR repertoire.
@en
P2093
P304
P356
10.4049/JIMMUNOL.164.2.596
P407
P577
2000-01-01T00:00:00Z